Triptamine prodrugs as serotonin receptor activators for the treatment of, for example, depression
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- REUNION NEUROSCIENCE INC MORRISTOWN
- Filing Date
- 2021-06-30
- Publication Date
- 2026-05-13
AI Technical Summary
Existing treatments for depression, particularly drug-resistant forms, often require multiple therapies and have variable efficacy due to unpredictable ester cleavage and species-specific esterase activity, limiting the effectiveness of tryptamine-based psychedelic compounds.
Development of novel tryptamine prodrugs, such as psilocin-4-succinate and N,N diisopropyltryptamine-4-glutarate, which convert to active 5HT2A agonists in vivo, providing a controlled psychedelic state for therapeutic effects without rapid onset, and are designed for solubility and stability, reducing potential for abuse.
These prodrugs offer prolonged therapeutic benefits lasting over months, reducing the need for additional therapy and minimizing abuse potential, while ensuring solubility and stability, and providing a controlled psychedelic experience for treating depression.